A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
Conditions
- Hormone Receptor Positive
- HER2-low or HER2-ultralow
- Unresectable or Metastatic Breast Cancer
Interventions
- DRUG: Patritumab deruxtecan
- DRUG: Trastuzumab deruxtecan
Sponsor
Daiichi Sankyo
Collaborators